| PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms F Briest, P Grabowski Theranostics 4 (4), 336, 2014 | 106 | 2014 |
| The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models S Nölting, J Rentsch, H Freitag, K Detjen, F Briest, M Möbs, V Weissmann, ... PLoS One 12 (8), e0182852, 2017 | 36 | 2017 |
| FOXM1: A novel drug target in gastroenteropancreatic neuroendocrine tumors F Briest, E Berg, I Grass, H Freitag, D Kaemmerer, F Lewens, F Christen, ... Oncotarget 6 (10), 8185, 2015 | 33 | 2015 |
| Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer S Taromi, F Lewens, R Arsenic, D Sedding, J Sänger, A Kunze, M Moebs, ... Oncotarget 8 (57), 97061, 2017 | 26 | 2017 |
| Inhibition of mTOR's catalytic site by PKI-587 is a promising therapeutic option for gastroenteropancreatic neuroendocrine tumor disease H Freitag, F Christen, F Lewens, I Grass, F Briest, S Iwaszkiewicz, ... Neuroendocrinology 105 (1), 90-104, 2017 | 24 | 2017 |
| Vandetanib therapy in medullary thyroid cancer P Grabowski, F Briest, RP Baum, JJ Zaknun, HR Kulkarni, M Zeitz, ... Drugs of Today 48 (11), 723, 2012 | 22 | 2012 |
| Tumor-stroma interactions in tumorigenesis: lessons from stem cell biology F Briest, A Berndt, J Clement, K Junker, F von Eggeling, S Grimm, ... Frontiers in Bioscience-Elite 4 (5), 1871-1887, 2012 | 22 | 2012 |
| The p53 network as therapeutic target in gastroenteropancreatic neuroendocrine neoplasms F Briest, P Grabowski Cancer treatment reviews 41 (5), 423-430, 2015 | 21 | 2015 |
| A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: results from the CONKO-005 trial K Hoyer, R Hablesreiter, Y Inoue, K Yoshida, F Briest, F Christen, ... EBioMedicine 66, 2021 | 18 | 2021 |
| Modeling clonal hematopoiesis in umbilical cord blood cells by CRISPR/Cas9 F Christen, R Hablesreiter, K Hoyer, C Hennch, A Maluck-Böttcher, ... Leukemia 36 (4), 1102-1110, 2022 | 16 | 2022 |
| Immunoprofiling in neuroendocrine neoplasms unveil immunosuppressive microenvironment A Busse, LH Mochmann, C Spenke, R Arsenic, F Briest, K Jöhrens, ... Cancers 12 (11), 3448, 2020 | 16 | 2020 |
| Immunohistochemical study of mitosis-regulatory proteins in Gastroenteropancreatic neuroendocrine neoplasms F Briest, Y Wang, R Arsenic, S Elezkurtaj, E Berg, S Greshake, AC Lock, ... Anticancer Research 38 (7), 3863-3870, 2018 | 11 | 2018 |
| Mechanisms of targeting the MDM2-p53-FOXM1 axis in well-differentiated intestinal neuroendocrine tumors F Briest, I Grass, D Sedding, M Möbs, F Christen, J Benecke, K Fuchs, ... Neuroendocrinology 107 (1), 1-23, 2018 | 10 | 2018 |
| Does the proteasome inhibitor bortezomib sensitize to DNA-damaging therapy in gastroenteropancreatic neuroendocrine neoplasms?–A preclinical assessment in vitro and in vivo F Briest, EJ Koziolek, J Albrecht, F Schmidt, MR Bernsen, J Haeck, ... Neoplasia 23 (1), 80-98, 2021 | 9 | 2021 |
| Genetic characterization of primary mediastinal B-cell lymphoma: pathogenesis and patient outcomes D Noerenberg, F Briest, C Hennch, K Yoshida, R Hablesreiter, Y Takeuchi, ... Journal of Clinical Oncology 42 (4), 452-466, 2024 | 4 | 2024 |
| Frequent ZNF217 mutations lead to transcriptional deregulation of interferon signal transduction via altered chromatin accessibility in B cell lymphoma F Briest, D Noerenberg, C Hennch, K Yoshida, R Hablesreiter, J Nimo, ... Leukemia 37 (11), 2237-2249, 2023 | 3 | 2023 |
| 455 role of MDM2 as therapeutic target in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) F Briest, I Grass, F Christen, F Lewens, H Freitag, D Kaemmerer, ... European Journal of Cancer, 149, 2014 | 3 | 2014 |
| S101: GENETIC AND EPIGENETIC FACTORS DRIVING PRIMARY MEDIASTINAL B‐CELL LYMPHOMA PATHOGENESIS AND OUTCOME D Noerenberg, F Briest, C Hennch, K Yoshida, J Nimo, R Hablesreiter, ... HemaSphere 6, 2-3, 2022 | 2 | 2022 |
| Expression of FOXM1 in G3 neuroendocrine tumors (NET G3) and G3 neuroendocrine carcinomas (NEC G3) of the pancreas and the intestine F Briest, M Konukiewitz, M Anlauf, G Klöppel, P Grabowski, B Sipos 15th Annual ENETS conference, 7-9, 2018 | 1 | 2018 |
| Concomitant inhibition of PI3K/mTOR signaling pathways boosts antiproliferative effects of lanreotide in bronchopulmonary neuroendocrine tumor cells C von Hessert-Vaudoncourt, S Lelek, C Geisler, T Hartung, V Bröker, ... Frontiers in Pharmacology 15, 1308686, 2024 | | 2024 |
Carsten GrötzingerGroup Leader, Cancer Research, Charité BerlinGeverifieerd e-mailadres voor charite.de
